AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
Previous Symbol
CUSIPN/A
Phone386-462-6800
Debt
Debt-to-Equity RatioN/A
Current Ratio12.72
Quick Ratio11.81
Price-To-Earnings
Trailing P/E Ratio-108.81
Forward P/E Ratio-57.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$60.43 million
Price / Sales21.21
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book45.20
Profitability
EPS (Most Recent Fiscal Year)($0.31)
Net Income$-10,440,000.00
Net Margins-25.39%
Return on Equity-18.17%
Return on Assets-14.44%
Miscellaneous
Employees199
Outstanding Shares38,320,000
Market Cap$1.39 billion
OptionableOptionable
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) issued its earnings results on Monday, October, 29th. The medical equipment provider reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The medical equipment provider had revenue of $22.66 million for the quarter, compared to analyst estimates of $22.52 million. AxoGen had a negative net margin of 25.39% and a negative return on equity of 18.17%. The firm's revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.04) earnings per share. View AxoGen's Earnings History.
When is AxoGen's next earnings date?
What guidance has AxoGen issued on next quarter's earnings?
AxoGen issued an update on its FY 2018 earnings guidance on Monday, October, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $84.597 million, compared to the consensus revenue estimate of $84.71 million.
What price target have analysts set for AXGN?
7 brokers have issued 12 month target prices for AxoGen's stock. Their forecasts range from $27.00 to $55.00. On average, they anticipate AxoGen's stock price to reach $41.8333 in the next year. This suggests a possible upside of 24.2% from the stock's current price. View Analyst Price Targets for AxoGen.
What is the consensus analysts' recommendation for AxoGen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.
Has AxoGen been receiving favorable news coverage?
Media coverage about AXGN stock has trended somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AxoGen earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), Electrocore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Fonar (FONR), Second Sight Medical Products (EYES), Zynex (ZYXI), Viveve Medical (VIVE) and Stereotaxis (STXS).
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Chairman, Pres & CEO (Age 56)
- Mr. Peter J. Mariani, Chief Financial Officer (Age 54)
- Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel, Sr. VP of Bus. Devel. & Director (Age 56)
- Mr. Shawn F. McCarrey, Sr. VP of Sales (Age 60)
- Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)
Who are AxoGen's major shareholders?
AxoGen's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.54%), Alliancebernstein L.P. (3.48%), FMR LLC (2.97%), Bank of New York Mellon Corp (2.88%), Eagle Asset Management Inc. (2.46%) and Wells Fargo & Company MN (2.30%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Guido J Neels, Jamie Mark Grooms, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.
Which institutional investors are selling AxoGen stock?
AXGN stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Gilder Gagnon Howe & Co. LLC, Russell Investments Group Ltd., Lisanti Capital Growth LLC, AWM Investment Company Inc., Perkins Capital Management Inc., Credit Suisse AG and Rhumbline Advisers. Company insiders that have sold AxoGen company stock in the last year include Guido J Neels, Jamie Mark Grooms and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen.
Which institutional investors are buying AxoGen stock?
AXGN stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Alliancebernstein L.P., Peregrine Capital Management LLC, Bank of New York Mellon Corp, Wells Fargo & Company MN, BlackRock Inc., Biondo Investment Advisors LLC and Pennsylvania Trust Co. View Insider Buying and Selling for AxoGen.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $33.69.
How big of a company is AxoGen?
AxoGen has a market capitalization of $1.39 billion and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen employs 199 workers across the globe.
What is AxoGen's official website?
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (NASDAQ AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
